Sledování nákladné pneumoonkologické léčby pokročilého nemalobuněčného karcinomu plic v první linii v registru TULUNG v České republice (stav k 15.3.2017)

Title in English Follow-up of costly pneumooncological treatment of advanced NSCLC with first-line treatment according to the TULUNG registry in the Czech Republic (up to March 15, 2017)
Authors

SKŘIČKOVÁ Jana CHLOUPKOVÁ Renata KONEČNÝ Marek PEŠEK Milan ZATLOUKAL Petr KOLEK Vítězslav SALAJKA František HRNČIARIK Michal KOUBKOVÁ Leona TOMÍŠKOVÁ Marcela GRYGÁRKOVÁ Yvona HAVEL Libor ZEMANOVÁ Milada SIXTOVÁ dimka ROUBEC Jaromír ČOUPKOVÁ Leona ČERNOVSKÁ Markéta OPÁLKA Petr KREJČÍ Jana ŠATÁNKOVÁ Monika BENEJOVÁ Andrea MAREL Miroslav VAŠÁKOVÁ Martina

Year of publication 2017
Type Popularization text
MU Faculty or unit

Faculty of Medicine

Citation
Description Five drugs (pemetrexed,erlotinib, bevacizumab, gefinitib and afatinib) were used as first-line treatment of non-small cell lung cancer (NSCLC) in 2234 patients in the Czech Republic between 2006 and 2017. A detailed morphological and genetic analysis of NSCLC was available. The outcomes of treatment are analysed.

You are running an old browser version. We recommend updating your browser to its latest version.

More info